Cantargia receives Notice of Allowance in the US for the CAN04 patent application
The United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Cantargia AB’s (“Cantargia”) patent application for its CAN04 product candidate, which means that the USPTO intends to approve the company’s application. Cantargia has previously received an intention to grant notification for CAN04 in Europe.
The patent application, no. 15/255,585, for which the USPTO has granted Notice of Allowance refers to the company’s CAN04 product candidate. The patent protects Cantargia’s product candidate, the CAN04 antibody, which is targeted against the IL1RAP target molecule generally as a substance and specifically for treatment of various forms of cancer. Notice of Allowance indicates that the USPTO intends to approve the company’s patent application as soon as a number of minor administrative steps have been completed. The patent provides protection in the United States until 2035.
In addition to the US, Cantargia’s patent application for CAN04 has recently received an intention to grant notification in Europe and is being examined in several countries, including India, Japan and China.
“We are very pleased that both the US and European patent offices have notified that they intend to approve our application for Cantargia’s CAN04 product candidate”, Göran Forsberg, CEO of Cantargia, says. “Our patent portfolio has reached a higher level, as we already have approved patents for treatment of various forms of cancer using antibodies against IL1RAP”.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 21 June 2017, at 8.45am.
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.
Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.